Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denis Maillet

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Cancer Chemotherapy and Pharmacology|February 25, 2023
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumorsRomain Varnier, Alicja Puszkiel, Michel Tod, et al.
European Journal of Cancer (Oxford, England : 1990)|April 15, 2014
Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancerAntoine Angelergues, Denis Maillet, Aude Fléchon, et al.
Oncotarget|April 21, 2017
Ephrin-B3 supports glioblastoma growth by inhibiting apoptosis induced by the dependence receptor EphA4Amélie Royet, Laura Broutier, Marie-May Coissieux, et al.
Cell Death and Differentiation|June 2, 2018
The Ectodysplasin receptor EDAR acts as a tumor suppressor in melanoma by conditionally inducing cell deathJonathan Vial, Amélie Royet, Philippe Cassier, et al.
European Journal of Cancer (Oxford, England : 1990)|September 17, 2023
Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric studyEdwige Baudry, Natacha Naoun, Edouard Auclin, et al.
European Urology Oncology|November 18, 2025
Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel StudyAndrew J Armstrong, Fred Saad, Mototsugu Oya, et al.
International Journal of Cancer|May 23, 2022
Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR studyYann-Alexandre Vano, Letuan Phan, Gwenaelle Gravis, et al.
European Journal of Cancer (Oxford, England : 1990)|September 11, 2022
Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinomaLucie Meynard, Derek Dinart, Blandine Delaunay, et al.
European Urology Oncology|April 6, 2024
Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel TrialFred Saad, Andrew J Armstrong, Mototsugu Oya, et al.
British Journal of Cancer|February 6, 2026
Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK studyBenoit Blanchet, Alicja Puszkiel, Anne Jouinot, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Cancer Chemotherapy and Pharmacology|February 25, 2023
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumorsRomain Varnier, Alicja Puszkiel, Michel Tod, et al.
European Journal of Cancer (Oxford, England : 1990)|April 15, 2014
Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancerAntoine Angelergues, Denis Maillet, Aude Fléchon, et al.
Oncotarget|April 21, 2017
Ephrin-B3 supports glioblastoma growth by inhibiting apoptosis induced by the dependence receptor EphA4Amélie Royet, Laura Broutier, Marie-May Coissieux, et al.
Cell Death and Differentiation|June 2, 2018
The Ectodysplasin receptor EDAR acts as a tumor suppressor in melanoma by conditionally inducing cell deathJonathan Vial, Amélie Royet, Philippe Cassier, et al.
European Journal of Cancer (Oxford, England : 1990)|September 17, 2023
Efficacy and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: A retrospective multicentric studyEdwige Baudry, Natacha Naoun, Edouard Auclin, et al.
European Urology Oncology|November 18, 2025
Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel StudyAndrew J Armstrong, Fred Saad, Mototsugu Oya, et al.
International Journal of Cancer|May 23, 2022
Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR studyYann-Alexandre Vano, Letuan Phan, Gwenaelle Gravis, et al.
European Journal of Cancer (Oxford, England : 1990)|September 11, 2022
Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinomaLucie Meynard, Derek Dinart, Blandine Delaunay, et al.
European Urology Oncology|April 6, 2024
Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel TrialFred Saad, Andrew J Armstrong, Mototsugu Oya, et al.
British Journal of Cancer|February 6, 2026
Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK studyBenoit Blanchet, Alicja Puszkiel, Anne Jouinot, et al.
Pageof 7